Medscape

Carboplatin Plus Pemetrexed as First-line Treatment of Patients with Malignant Pleural Mesothelioma: A Phase II Study

Introduction: Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is increasing in frequency worldwide. Treatment options are limited, and response to chemotherapy is poor. The ...
Morningstar

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

Paris, France, June 4th, 2025. Oncovita, a biotechnology company developing innovative virus-based immunotherapies for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA ...
Business Wire

Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions

TOKYO & AUSTIN, Texas--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd, (“Taiho”) and Lung Therapeutics, Inc. (“Lung Tx”) announced today an exclusive license agreement of LTI-01, a recombinant human ...
JSTOR Daily

Pleural abnormalities in the Framingham Heart Study: prevalence and CT image features

Tetsuro Araki, Masahiro Yanagawa, Fangui Jenny Sun, Josée Dupuis, Mizuki Nishino, Yoshitake Yamada, George R Washko, David C Christiani, Noriyuki Tomiyama, George T O’Connor, Gary M Hunninghake, ...
JSTOR Daily

The Additional Risk of Malignant Mesothelioma in Former Workers and Residents of Wittenoom with Benign Pleural Disease or Asbestosis

Aims: To examine the hypothesis that people with benign pleural disease or asbestosis have an increased risk of malignant mesothelioma beyond that attributable to their degree of asbestos exposure.